New hope for PNH patients: Long-Term safety trial of HRS-5965 underway
NCT ID NCT06238544
First seen Jan 04, 2026 · Last updated May 08, 2026 · Updated 25 times
Summary
This study looks at the long-term safety of a drug called HRS-5965 in people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Participants who previously took HRS-5965 and benefited from it will continue taking it. Researchers will track side effects and how well the drug controls the disease over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100730, China
-
The Blood Disease Hospital of the Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.